Skip to main content
Fig. 7 | Experimental Hematology & Oncology

Fig. 7

From: G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt/β-catenin pathway

Fig. 7

DHEA relieves G6PD-mediated Dexa resistance in MM cells. a–c The sensitivity to Dexa was assessed in MM1.S WT (a), ARP1 (b) and H929 (c) G6PD-OE MM cells treated with DHEA for 48 h. d-e WB analysis showed the expression levels of β-catenin and G6PD in ARP1 (d) and H929 (e) G6PD-OE cells treated with DHEA and Dexa individually or combined. f, g Intracellular oxidative activity was not altered significantly upon Dexa treatment in ARP1 (f) and H929 (g) G6PD-OE cells. h-i DHEA effectively increased ROS content in ARP1 (h) and H929 (i) G6PD-OE cells treated with Dexa. *p < 0.05 was considered statistically significant

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us